Results of a men's urological health screening program at Lockheed Martin Aeronautical Systems

Disease Management and Health Outcomes

Volumn 11, Issue 3, 2003, Pages 181-189

  Thomas, Pamella ^a   Goetzel, Ron Z ^b   Ozminkowski, Ronald J ^c   Kassabian, Vahan S ^d,e   Schutt, David C ^c  

^a Lockheed Aeronautical Systems Company   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c MEDSTAT GROUP   (United States)

^d Georgia Urology   (United States)

^e Georgia Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ERECTILE DYSFUNCTION; HUMAN; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUESTIONNAIRE; SCREENING; UROLOGIC EXAMINATION;

EID: 0037288313     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200311030-00005     Document Type: Article

References (24)

1. Fielding JE, Knight KK, Goetzel RZ, et al. Prevalence and characteristics of employees reporting 'heavy' or 'problem' drinking. Prev Med 1991; 20: 316-27
2. Centers for Disease Control and Prevention, National Center for Health Statistics, Division of Health Interview Statistics. Health, United States. Silver Spring (MD): National Center for Health Statistics, 1998
3. Fielding JE, Knight KK, Goetzel RZ. Utilization of preventive health services by an employed population. J Occup Med 1991; 33: 985-90
4. Westra CS, Ducatman AM, Niewiadomska-Bugaj M, et al. An estimate of prostate cancer prevalence for a demographically similar workforce population. W V Med J 1999; 95: 116-21
5. Myers RE, Vernon SW, Carpenter AV, et al. Employee response to a company-sponsored program of colorectal and prostate cancer screening. Cancer Detect Prev 1997; 21: 380-9
6. Ozminkowski RJ, Mark T, Cangianelli L, et al. The cost of on-site vs off-site workplace urinalysis testing for illicit drug use. Health Care Manag (Frederick) 2001; 20: 59-69
7. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30
8. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36
9. McNeal JE. The prostate gland: morphology and pathobiology [editorial]. Mol Urol 1988; 9: 3
10. Stamey TA. Pathogenesis and treatment of urinary tract infections. Baltimore (MD): Williams and Wilkins, 1980
11. National Institute of Health Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90
12. US Bureau of the Census. Statistical Abstract of the United States: 1997. Washington, DC: US Bureau of the Census, 1997
13. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
14. Curkendall SM, Jones JK, Glasser D, et al. Incidence of medically detected erectile dysfunction and related diseases before and after Viagra (sildenafil citrate). Eur Urol 2000; 37 Suppl. 2: 1-75
15. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23
16. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 51: 1283-90
17. Netto Junior NR, de Lima ML. The influence of patient education level on the International Prostatic Symptom Score. J Urol 1995; 154 (1): 97-9
18. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-9
19. Kolata G. Prostate cancer surgery found to cut death risk. New York Times 2002 Sep 12, Health section, 1
20. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996
21. American College of Preventive Medicine Medical Specialty Society. Cited by the National Guideline Clearinghouse. Screening for prostate cancer in American men, 1998 [online]. Available from URL: http://www.guideline.gov [Accessed 2002 June]
22. American Cancer Society. Prostate cancer treatment guidelines for patients, Version II. Atlanta (GA): American Cancer Society, 2001 Jan
23. Snyder C, Schrammel PN, Griffiths CB, et al. Prostate cancer screening in the workplace. AAOHN J 1998; 46: 379-84
24. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990; 17: 719-37